Meet Kelly Chien, M.D.
Kelly S. Chien, M.D.
Department of Leukemia, Division of Cancer Medicine
In the News
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2008 | Massachusetts Institute of Technology, Cambridge, Massachusetts, US, SB in Chemical Engineering |
| 2008 | Massachusetts Institute of Technology, Cambridge, Massachusetts, US, SB in Biology |
Postgraduate Training
| 2019-2020 | Hematology Chief Fellow, Hematology/Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2019 | Clinical Fellowship, Hematology/Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2016 | Clinical Residency, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas |
| 2013-2014 | Clinical Internship, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas |
Licenses & Certifications
| 2020 | Hematology |
| 2020 | Medical Oncology |
| 2019 | Texas State Medical License |
| 2016 | American Board of Internal Medicine Certification |
| 2016 | New York State Medical License |
Experience & Service
Faculty Academic Appointments
Instructor, Medicine, New York University Langone Medical Center, New York, NY, 2016 - 2017
Extramural Institutional Committee Activities
Member, NCCN MDS Panel, National Comprehensive Cancer Network, 2025 - Present
Chair, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2025 - Present
Vice Chair, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2024 - Present
Faculty Advisor, Leukemia Education APP Program, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Joint Steering Committee for the Astex (Taiho)/MDACC Alliance, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Joint Steering Committee for the Rigel/MDACC Alliance, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Utilization Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Committee Member, Clinic to ACCC Handoff Team, The University of Texas MD Anderson Cancer Center, 2021 - Present
Leukemia MD Champion, PROSPECT Trial, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Honors & Awards
| 2025 - 2028 | Robert A. Winn Career Development Award, Robert A. Winn Excellence In Clinical Trials Award Program |
| 2022 | Waun Ki Hong Award for Excellence in Team Science, The University of Texas MD Anderson Cancer Center |
| 2022 | Travel Grant, European Hematology Association |
| 2020 | Kimberly Patterson Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center |
| 2020 | Waun Ki Hong Award for Achievement in Clinical Investigation, The University of Texas MD Anderson Cancer Center |
| 2019 | Oncology Fellows Program Participant, National Comprehensive Cancer Network Annual Meeting |
| 2019 | Conquer Cancer Foundation Young Investigator Award, American Society of Clinical Oncology |
| 2019 | Merit Award, American Society of Clinical Oncology Annual Meeting |
| 2018 | Abstract Achievement Award, American Society of Hematology Annual Meeting |
| 2016 | Internal Medicine Resident Teaching Award Honorable Mention, University of Texas Southwestern Medical Center |
| 2014 | Internal Medicine Intern Teaching Award Honorable Mention, University of Texas Southwestern Medical Center |
| 2008 | Top 5, MIT 6.270 Autonomous Robot Competition |
| 2004 | National Merit Scholar, National Merit Scholarship Program |
| 2004 | Semi-Finalist, Young Epidemiology Scholars Competition |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Risk Stratification in Myelodysplastic Syndromes. Invited. Leukemia Research Conference. Houston, Texas, US.
- 2026. Myelodysplastic Syndromes/Neoplasms. Invited. UCSF Fresno Grand Rounds. Fresno, CA, US.
- 2025. Malignant Hematology Q&A Session. Invited. MD Anderson Hematology/Medical Oncology Board Review. Houston, Texas, US.
- 2025. ASH 2024: Clinical Updates in CHIP/CCUS. Invited. Leukemia Research Meeting, US.
- 2024. Myelodysplastic Syndromes: Introduction and Treatment Options. Invited. MDS Patient Conference. Houston, Texas, US.
- 2023. Patterns of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2022. Risk Stratification of Myelodysplastic Syndromes. Invited. Practical Approach of AML and MDS Treatment. Houston, Texas, US.
- 2022. Malignant Hematology Q&A Session. Invited. MD Anderson Hematology/Medical Oncology Board Review. Houston, TX, US.
- 2022. Clonal Hematopoiesis of Emerging Significance: An Introduction to the MD Anderson CHIP & Leukemia Prevention Clinic. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2022. Clonal Hematopoiesis of Emerging Significance: An Introduction to the MD Anderson CHIP & Leukemia Prevention Clinic. Invited. Division of Cancer Medicine Grand Rounds. Houston, TX, US.
- 2021. Malignant Hematology Q&A Session. Invited. MD Anderson Hematology/Medical Oncology Board Review. Houston, TX, US.
- 2020. Prevention of Therapy-Related Myeloid Neoplasms with CHIP. Invited. T32 Research Symposium. Houston, TX, US.
- 2019. Prevention of Therapy-Related Myeloid Neoplasms with CHIP. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2008. Quantitative Proteomic Analysis of the Met Signaling Network. Conference. Massachusetts Institute of Technology Center for Environmental Health Sciences Annual Poster Session. Cambridge, MA, US.
Regional Presentations
- 2016. Mysterious Abdominal Pain and Inadvertent latrogenesis. Conference. 2016 Society of General Internal Medicine Southern Regional Meeting. Atlanta, GA, US.
- 2012. Thrombotic Thrombocytopenic Purpura in HIV: Not the Usual Suspect. Conference. 2012 Texas Chapter of the American College of Physicians Annual Meeting. Fort Worth, TX, US.
National Presentations
- 2026. Clinical Trials 1: Eligibility and Efficacy - Acceptable Endpoints. Invited. Therapeutic Interventions in CCUS and Other Related Myeloid Precursor States FDA Minisymposium, US.
- 2025. Outcomes of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2025 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2025. Outcomes of Clinical Trial Screening in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Conference. 2025 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2025. Phase II Study Evaluating Olutasidenib in Patients with IDH1-Mutated Clonal Cytopenia of Undetermined Significance or Lower-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia. Conference. 2025 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2025. ACVR1 Expression in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Based on Response to Hypomethylating Agents. Conference. 2025 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2025. Phase II Study Evaluating Olutasidenib and Azacitidine in Patients with IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasms. Conference. 2025 American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
- 2025. Phase II Study Evaluating Olutasidenib in Patients with IDH1-Mutated Clonal Cytopenia of Undetermined Significance or Lower-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia. Conference. 2025 American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
- 2025. YES: Pre-Emptive Treatment of Pre-MDS in the Future. Invited. 2025 MPN-MDS US Focus Meeting. Austin, TX, US.
- 2024. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis. Conference. 2024 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2024. Risk Stratification in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes: A Multivariate Model. Conference. 2024 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2024. A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients with Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure. Conference. 2024 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2024. A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients with Myelodysplastic Syndrome After Hypomethylating Agent Failure. Conference. 2024 American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
- 2023. Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2023 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2023. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes. Conference. 2023 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2023. Outcomes of Individuals with Clonal Hematopoiesis Evaluated at a Cancer Center. Conference. 2023 American Society of Clinical Oncology Annual Meeting. Houston, Texas, US.
- 2022. Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure. Conference. 2022 American Society of Hematology Annual Meeting. New Orleans, LA, US.
- 2022. Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Conference. 2022 American Society of Hematology Annual Meeting. Houston, Texas, US.
- 2022. Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2022 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2020. Final Results from a Phase II Study of Azacitidine and Pembrolizumab in Higher-Risk Myelodysplastic Syndrome after Hypomethylating Agent Failure. Conference. 2020 American Society of Hematology Annual Meeting, US.
- 2020. Updated Results from a Phase II Study of Azacitidine and Pembrolizumab in Higher-Risk Untreated Myelodysplastic Syndrome. Conference. 2020 American Society of Hematology Annual Meeting, US.
- 2019. Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome. Conference. 2019 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2019. Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Conference. 2019 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2019. The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Conference. 2019 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2019. LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents. Conference. 2019 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2019. Patterns of Leukemic Transformation in Patients with TP53-Mutant Myelodysplastic Syndromes. Conference. 2019 American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
- 2018. Safety and Tolerability of Lurbinectedine (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Conference. 2018 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2018. Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Conference. 2018 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2008. Quantitative Proteomic Analysis of the Met Signaling Network. Conference. American Association of Cancer Research Epithelial-Mesenchymal Transition Meeting. Cold Harbor Springs, NY, US.
International Presentations
- 2025. Clinical Trials in CCUS. Invited. 4th Annual Bermuda Translational Summit on Hematologic Malignancies, BM.
- 2025. Early Intervention in Transfusion-Independent MDS. Invited. 4th Bermuda Translational Summit on Hematologic Malignancies, BM.
- 2025. Risk Stratification in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes: A Multivariate Model (MDS-HOPE). Conference. 2025 European Hematology Association Annual Congress. Milan, IT.
- 2024. Lower-Risk Myelodysplastic Syndromes: New Therapeutic Strategies. Invited. 2nd Dasa Hematology Symposium. Sao Paulo, BR.
- 2024. A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients with Myelodysplastic Syndrome After Hypomethylating Agent Failure. Conference. 2024 European Hematology Association Annual Congress. Madrid, ES.
- 2024. Genomic Evolution of Patients with Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis. Conference. 2024 European Hematology Association Annual Congress. Madrid, ES.
- 2024. Risk Stratification in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes: A Multivariate Model. Conference. 2024 European Hematology Association Annual Congress. Madrid, ES.
- 2023. Evolution of IPSS-M Risk Categories in Patients with Myelodysplastic Syndromes from Diagnosis to Hypomethylating Agent Failure. Conference. 2023 European Hematology Association Annual Congress. Frankfurt, DE.
- 2022. Patterns of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2022 European Hematology Association Annual Congress. Vienna, AT.
Grant & Contract Support
| Date: | 2026 - 2027 |
| Title: | Preventing Therapy-Related Leukemia in Cancer Patients with Pre-Malignant Clonal Hematopoiesis |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | FP00028868 |
| Date: | 2026 - 2027 |
| Title: | BTC4ALL Clinical Trials Working Group |
| Funding Source: | Breakthrough Cancer |
| Role: | PI |
| Date: | 2025 - 2028 |
| Title: | Improving Clinical Trial Accessibility for Leukemia Prevention and Treatment |
| Funding Source: | Robert A. Winn Excellence in Clinical Trials Award Program |
| Role: | PI |
| Date: | 2024 - 2030 |
| Title: | 2024-0515: A phase 2 study investigating the combination of olutasidenib and azacitidine in patients with IDH1-mutated higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or advanced myeloproliferative neoplasms |
| Funding Source: | Rigel Pharmaceuticals |
| Role: | PI |
| Date: | 2024 - 2030 |
| Title: | 2024-0509: A phase 2 study investigating olutasidenib monotherapy in patients with IDH1-mutated clonal cytopenia of undetermined significance or lower-risk myelodysplastic syndromes/chronic myelomonocytic leukemia |
| Funding Source: | Rigel Pharmaceuticals |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | Targeting Clonal Hematopoiesis to Prevent AML |
| Funding Source: | Break Through Cancer |
| Role: | Co-PI |
| Date: | 2022 - 2027 |
| Title: | 2021-0276: A Phase 1 Study of AMG 176 as Monotherapy and in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia |
| Funding Source: | Amgen |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | An Integrated Approach Towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes |
| Funding Source: | The University of Texas MD Anderson Cancer Center IRG/MRP |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | 2021-0497: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications |
| Funding Source: | Karyopharm |
| Role: | Co-PI |
| Date: | 2019 - 2020 |
| Title: | Prevention of Therapy-Related Myeloid Neoplasms with Clonal Hematopoiesis of Indeterminate Potential |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | NIH/NCI Research Training in Academic Medical Oncology |
| Funding Source: | NIH/NCI |
| Role: | Trainee |
| ID: | T32 CA009666-24 |
| Date: | 2013 - 2023 |
| Title: | MDS/AML Moon Shot |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Chien KS, DeZern AE. The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat. Haematologica, 2026. e-Pub 2026. PMID: 41742893.
- Chien KS, Loghavi S, Sasaki K, McCue D, Daver NG, Kadia TM, Ravandi F, Short NJ, Issa GC, Montalban-Bravo G, Haddad FG, Hammond DE, Swaminathan M, Bazinet A, Bataller A, Bouligny I, Pierce SA, Garcia-Manero G, Kantarjian HM, DiNardo CD. Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. Clin Lymphoma Myeloma Leuk 26(2):e223-e228.e3, 2025. e-Pub 2025. PMID: 41469316.
- Chien KS, Curry JL, Pemmaraju N, Jain N. Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia. Am J Hematol 100(7):1240-1241, 2025. e-Pub 2025. PMID: 40062658.
- Urrutia S, Chien KS, Li Z, Bazinet A, Tang G, Garcia-Manero G. Cytogenetic annotation automation in myelodysplastic syndrome research databases. Blood Adv 9(10):2428-2430, 2025. e-Pub 2025. PMID: 39983082.
- Chien KS, Braish JS, Li Z, Loghavi S, Bataller A, Montalban-Bravo G, Sasaki K, Kanagal-Shamanna R, Takahashi K, DiNardo CD, Swaminathan M, Kantarjian HM, Garcia-Manero G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39(5):1269-1272, 2025. e-Pub 2025. PMID: 40175627.
- Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med 13(5):e7093, 2024. e-Pub 2024. PMID: 38497538.
- Chien KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. Blood Adv 7(19):5691-5697, 2023. e-Pub 2023. PMID: 36696472.
- Reztsova M, Chien KS, Post KT, Canales A, Yokota S. Bladder perforation as a rare complication of urethra sounding with a blunt marking pen. J Surg Case Rep 2023(2):rjad032, 2023. e-Pub 2023. PMID: 36778966.
- Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
- Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
- Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. e-Pub 2022. PMID: 36163972.
- Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
- Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2019. PMID: 30153704.
- Farmakiotis D, Chien KS, Shum TC, Rodriguez-Barradas M, Musher DM. Photo quiz. To scan or not to scan?. Clin Infect Dis 56(7):1003, 1052-3, 2013. e-Pub 2013. PMID: 23463794.
Review Articles
- Chien KS, DiNardo CD, Garcia-Manero G. Clonal hematopoiesis: malignant implications, extrahematologic manifestations, and management. Clin Adv Hematol Oncol 22(7):320-327, 2024. e-Pub 2024. PMID: 39110659.
- Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol 95(11):1399-1420, 2020. e-Pub 2020. PMID: 32744763.
Abstracts
- Chien KS. Outcomes of Patients with IDH1-Mutated Myeloid Neoplasms Treated with Olutasidenib. 2025 American Society of Hematology Annual Meeting, 2025. e-Pub 2025.
- Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Outcomes of Individuals with Clonal Hematopoiesis Evaluated at a Cancer Center. 2023 European Hematology Association Annual Congress, 2023. e-Pub 2023.
Book Chapters
- Chien KS, Bueso-Ramos C, Garcia-Manero G. Chapter 5: Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach. In: The MD Anderson Manual of Medical Oncology, Fourth Edition, 2022.
Letters to the Editor
- Chien KS, Li Z, Lanino L, Ali NA, Urrutia S, Bataller A, Kanagal-Shamanna R, Loghavi S, Lyu Y, Abdelhakeem A, Abuasab T, Almanza E, Ricos GG, Bazinet A, Campagna A, Maggioni G, Padron E, Xie Z, Montalban-Bravo G, Short NJ, Jabbour EJ, Kadia TM, Ravandi F, Borthakur G, DiNardo CD, Hammond D, Swaminathan M, Sasaki K, Dong XQ, Pierce SA, Sallman D, Kantarjian HM, Della Porta MG, Garcia-Manero G, Komrokji R. Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms. Leukemia 40: 841-844, 2026.
- Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
- Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98: E281-E284, 2023.
- Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127: 107044, 2023.
Patient Reviews
CV information above last modified July 22, 2026